Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [BUSINESS]
2 clusters · 10 sources · 4 days · First seen · Last updated
Evonik investment in Vancouver pharmaceutical facility
Overview
Evonik has announced an investment of over 150 million CAD (approximately 93 million EUR) to establish a new Good Manufacturing Practice (GMP) facility in Vancouver, Canada. The project is designed to expand the company’s development and production capacities for lipid-based drug delivery, specifically to support the production of vaccines, therapeutics, and other advanced medicines.
The new facility is expected to more than triple Evonik’s existing manufacturing capacity for advanced pharmaceutical products while enhancing quality control and microbiological testing capabilities to improve product release efficiency for clinical use. The Canadian federal government is supporting the initiative through the Strategic Response Fund, providing up to 68 million CAD (approximately 42 million EUR). Drug production at the site is scheduled to commence by the end of 2029.
Entities
Timeline
-
12 days ago
[BUSINESS] 3 sourcesEvonik to invest 93 million euros in Vancouver lipid-based drug productionEvonik is investing 150 million CAD to build a new GMP production facility in Vancouver, Canada, to triple its capacity for lipid-based drug delivery technologies by 2029.
-
16 days ago
[BUSINESS] 7 sourcesEvonik to invest 150 million CAD in Vancouver drug manufacturing facilityEvonik is investing over 150 million CAD in a new GMP manufacturing facility in Vancouver to expand lipid-based drug delivery capacity for vaccines and therapeutics.
Sources
aijourn.com · betakit.com · bionity.com · canadianmanufacturing.com · canplastics.com · chemengonline.com · healthcare-newsdesk.co.uk · laragione.eu · lospecialegiornale.it · pharmaindustrie-online.de